Moderate coding expectations
Systems engineers typically face medium-difficulty coding problems focused on automation, scripting, and infrastructure tooling rather than complex algorithms.
1 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
Systems engineers face unique technical challenges combining infrastructure knowledge with coding skills.. Explore key insights and preparation tips to help you excel in your interview process.
Systems engineers typically face medium-difficulty coding problems focused on automation, scripting, and infrastructure tooling rather than complex algorithms.
Design scalable infrastructure, monitoring systems, and deployment pipelines. Heavy emphasis on reliability and observability.
Infrastructure
CI/CD pipelines and deployment strategies
Monitoring
Observability and alerting systems
Reliability
High availability and disaster recovery
Different companies emphasize various aspects of systems engineering from cloud infrastructure to on-premise solutions.
Netflix
Microservices architecture and chaos engineering
Stripe
Payment infrastructure reliability and compliance
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers exceptional ROI for Systems Engineers with housing costs 70% lower than San Francisco and overall living expenses 68% more affordable. Your tech salary stretches significantly further while maintaining proximity to the DC-Baltimore tech corridor.
Baltimore's Systems Engineer market shows 28% job saturation versus 78% in San Francisco, creating better positioning for career advancement and salary negotiation.

New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States